drugset / Trial / NCT02553772

A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

NCT02553772

Phase 3 Completed 242 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of a new eye drop formulation in patients with dry eye disease.

Timeline

Start
2016-01-06
Primary completion
2016-09-09
Completion
2016-09-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboxymethylcellulose Other / unclassified 0.5 % Topical
Comparator Carboxymethylcellulose Other / unclassified Topical

Indications